- Home
- BUD vs JNJ Comparison
BUD vs JNJ Comparison
Compare BUD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUD | JNJ |
|---|---|---|
| Founded | 1366 | 1886 |
| Country | Belgium | United States |
| Employees | 136805 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7B | 542.4B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | BUD | JNJ |
|---|---|---|
| Price | $84.45 | $241.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | $92.00 | ★ $238.20 |
| AVG Volume (30 Days) | 1.7M | ★ 7.4M |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | 1.33% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.01 | $6.63 |
| Revenue Next Year | $3.67 | $7.43 |
| P/E Ratio | ★ $23.27 | $111.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.97 | $151.01 |
| 52 Week High | $84.46 | $251.71 |
Technical Indicators
Market Signals| Indicator | BUD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 60.83 |
| Support Level | $78.30 | $233.83 |
| Resistance Level | $84.46 | $244.80 |
| Average True Range (ATR) | 1.35 | 4.73 |
| MACD | 0.12 | 0.53 |
| Stochastic Oscillator | 94.44 | 86.93 |
Price Performance
Historical ComparisonAbout BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.